Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million [Yahoo! Finance]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Yahoo! Finance
stock options and sold 138,167 shares in open-market transactions for a total consideration of approximately $1.9 million, according to the SEC Form 4 filing Metric Value Shares sold (direct) Transaction value $1.9 million Post-transaction shares (direct) Post-transaction value (direct ownership) $48.33 million Transaction value based on SEC Form 4 weighted average purchase price ($13.59); post-transaction value based on Jan. 16, 2026 market close ($14.30). How does the size of this transaction compare to Cohen's historical selling activity? The 138,167 shares sold in this event are significantly larger than Cohen's historical median sell size of 15,220 shares since September 2024, representing an outlier primarily due to the option exercise and expiration context. How did the sale affect Cohen's direct ownership stake in Amylyx Pharmaceuticals? The transaction reduced Cohen's direct holdings by 3.93%, leaving him with 3,379,465 shares, which equated to an es
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSPR Newswire
- Amylyx Pharmaceuticals: Back From The Dead [Seeking Alpha]Seeking Alpha
- Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases [Yahoo! Finance]Yahoo! Finance
AMLX
Earnings
- 11/6/25 - Beat
AMLX
Sec Filings
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- AMLX's page on the SEC website